Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
2(11%)
Results Posted
40%(4 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_1
3
17%
Ph phase_4
3
17%
Ph phase_2
8
44%
Ph phase_3
3
17%
Ph not_applicable
1
6%

Phase Distribution

3

Early Stage

8

Mid Stage

6

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
3(16.7%)
Phase 2Efficacy & side effects
8(44.4%)
Phase 3Large-scale testing
3(16.7%)
Phase 4Post-market surveillance
3(16.7%)
N/ANon-phased studies
1(5.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.9%

10 of 13 finished

Non-Completion Rate

23.1%

3 ended early

Currently Active

2

trials recruiting

Total Trials

18

all time

Status Distribution
Active(2)
Completed(10)
Terminated(3)
Other(3)

Detailed Status

Completed10
unknown3
Recruiting2
Withdrawn2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
2
Success Rate
90.9%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (16.7%)
Phase 28 (44.4%)
Phase 33 (16.7%)
Phase 43 (16.7%)
N/A1 (5.6%)

Trials by Status

recruiting211%
withdrawn211%
unknown317%
terminated16%
completed1056%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT00208260Phase 2

Intensified Chemotherapy in CRC After Resection of Liver Metastases

Completed
NCT03092895Phase 2

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Completed
NCT06893887Not Applicable

Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

Recruiting
NCT02000050Phase 2

Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE)

Completed
NCT05912075Phase 1

Preoperative Radiotherapy And ASTX660 in Rectum Cancer

Recruiting
NCT03605706Phase 3

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.

Unknown
NCT00580073Phase 2

Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum

Terminated
NCT02534337Phase 2

Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma

Withdrawn
NCT02527772Phase 2

Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma

Withdrawn
NCT02069041Phase 1

A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer

Completed
NCT03084809Phase 4

Chemotherapy Combined With CIK Treating Colon Cancer

Completed
NCT01030042Phase 3

Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients

Completed
NCT02452853Phase 2

HR Combined With FOLFOX4 for HCC With PVTT

Unknown
NCT00202787Phase 2

Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer

Completed
NCT00349336Phase 3

A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.

Completed
NCT00101894Phase 1

Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

Completed
NCT00874406Phase 4

Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer

Unknown
NCT00869271Phase 4

Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer

Completed

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18